Sumitovant Biopharma Created and Launched as Sumitomo Dainippon Pharma and Roivant Sciences Close Transaction for Strategic Alliance – Sumitomo Dainippon Pharma and Roivant Sciences complete strategic alliance and formation of new company, Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Dainippon Pharma – Sumitovant will be led by Chief Executive Officer Myrtle Potter, former Roivant Vant Operating Chair and President and COO of Genentech – Roivant has received USD $3 billion from Sumitomo Dainippon Pharma for the transfer of Roivant’s ownership interests in five of its subsidiaries – Myovant, Urovant, Enzyvant, Altavant, and Spirovant – to Sumitovant, in addition to other technology assets and a stake in Roivant PR Newswire LONDON and NEW YORK, Dec. 30, 2019 LONDON and NEW YORK , Dec. 30, 2019 /PRNewswire/ — Sumitovant Biopharma Ltd. […]